XML 289 R36.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Investments In Subsidiaries (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Disclosure of subsidiaries [abstract] |
Non-controlling interests in subsidiaries - Balance Sheet |
| As of December 31
| 2021 | 2020
| $ millions | $ millions
Current assets | 231 | 149
Non-current assets | 408 | 400
Current liabilities | (168) | (189)
Non-current liabilities | (83) | (76)
Equity | (388) | (284)
Non-controlling interests in subsidiaries - Profit and Loss |
| For the year ended December 31
| 2021 | 2020 | 2019
| $ millions | $ millions | $ millions
Sales | 528 | 359 | 349
Operating Income | 105 | 29 | 23
Depreciation and amortization | 38 | 37 | 41
Operating income before depreciation and amortization | 143 | 66 | 64
Net Income | 96 | 23 | 11
Total Comprehensive income | 104 | 40 | 8
Disclosure of identifiable assets acquired and liabilities assumed |
| $ millions
Cash and cash equivalents | 34
Inventories | 102
Trade and Other receivables | 169
Property, plant and equipment | 125
Intangible assets | 252
Other non-current assets | 23
Trade and Other payables | (106)
Loans and Credit | (169)
Provisions | (3)
Net identifiable assets | 427
(*) As of the reporting date, the Company is still in a process of finalizing ADS' Purchase Price Allocation (PPA).
| (2) | In July 2021, the Company completed the sale of Jiaxing ICL Chemical Co. Ltd (ICL Zhapu), which was part of the Industrial Products segment to China Sanjiang Fine Chemicals Company Limited, for a consideration of about $25 million. As a result, in 2021, the Company recognized a capital gain of about $18 million, as "other income".
| (3) | As part of the Company's strategy to divest low synergy businesses and non-core business activities, in January 2022, the Company entered into a definitive agreement to sell its 50% share in the joint venture Novetide Ltd., which was accounted for according to the equity method. The sale's consideration is about $33 million, of which $8 million represent an estimate for the fair value of a contingent consideration. The closing of the transaction is expected in early March 2022. As a result, in the first quarter of 2022, the Company will recognize a capital gain of about $20 million, subject to net debt and working capital adjustments at the closing date.

X
- References No definition available. + Details
Name: | icl_DisclosureOfNoncontrollingInterestsPLExplanatory
Namespace Prefix: | icl_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of detailed information about business combinations. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Section Disclosures application of paragraphs 59 and 61 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of non-controlling interests. [Refer: Non-controlling interests] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration